Literature DB >> 3114300

Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature.

E Ghigo, E Mazza, E Imperiale, G Rizzi, L Benso, E E Müller, F Camanni, F Massara.   

Abstract

Increased cholinergic tone induced by pyridostigmine (PD) increases basal plasma GH levels and potentiates the GH response to GHRH in normal adults. In this study the effects of PD (60 mg, orally) on both basal and GHRH (1 microgram/kg)-induced GH secretion in seven children with familial short stature (FSS), six with GH deficiency (GHD) and 10 with constitutional growth delay (CGD) were studied and compared with results obtained by stimulation with insulin-induced hypoglycemia (IH) and GHRH alone. The mean peak plasma GH levels were variable, but individual values were frequently low in all groups after both IH [FSS, 9.7 +/- 1.3 (+/- SEM) ng/mL; GHD, 1.6 +/- 0.4 ng/mL; CGD, 7.0 +/- 0.8 ng/mL] and GHRH (FSS, 23.8 +/- 6.6 ng/mL; GHD, 11.1 +/- 5.8 ng/mL; CGD, 15.1 +/- 4.5 ng/mL) administration. PD induced GH responses (FSS, 14.5 +/- 1.6 ng/mL; GHD, 3.8 +/- 0.8 ng/mL; CGD, 18.3 +/- 3.2 ng/mL) that in many children in the FSS and CGD groups were higher than those after IH and GHRH treatment. PD clearly increased the GH response to GHRH in all children [FSS, 69.5 +/- 9.4 ng/mL (P less than 0.01 vs. other stimuli); GHD, 18.0 +/- 7.5 ng/mL; CGD, 50.0 +/- 8.5 ng/mL (P less than 0.01 vs. other stimuli)]. We conclude that in children with short stature, as in adults, enhancement of cholinergic tone increases both basal and GHRH-induced GH secretion, and that PD plus GHRH is the best provocative stimulus for evaluating the somatotroph response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114300     DOI: 10.1210/jcem-65-3-452

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Plasma GH responses to GHRH, arginine, L-dopa, pyridostigmine, sequential administrations of GHRH and combined administration of PD and GHRH in Turner's syndrome.

Authors:  K Hanew; A Tanaka; A Utsumi
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

2.  A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.

Authors:  E Ghigo; E Imperiale; G M Boffano; E Mazza; J Bellone; E Arvat; M Procopio; S Goffi; A Barreca; P Chiabotto
Journal:  J Endocrinol Invest       Date:  1990-04       Impact factor: 4.256

3.  Pyridostigmine and metoclopramide do not restore the TSH response to TRH inhibited by L-thyroxine treatment in children with goiter.

Authors:  G Radetti; S Bernasconi; M Bozzola; C Volta; G Tonini; L Gentili; F Rigon
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

4.  Effect of testosterone replacement therapy on the somatotrope responsiveness to GHRH alone or combined with pyridostigmine and on sympathoadrenal activity in patients with hypogonadism.

Authors:  G Del Rio; C Carani; A Velardo; G Zizzo; M Procopio; F Coletta; P Marrama; E Ghigo
Journal:  J Endocrinol Invest       Date:  1995-10       Impact factor: 4.256

5.  Hexarelin-induced growth hormone response in short stature. Comparison with growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen.

Authors:  G Guzzaloni; G Grugni; F Morabito
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

6.  The growth hormone response to pyridostigmine plus growth hormone releasing hormone is not influenced by pubertal maturation.

Authors:  M Cappa; S Loche; R Salvatori; A Faedda; P Borrelli; S G Cella; C Pintor; E E Müller
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

Review 7.  Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; V Locatelli; E Ghigo; S G Cella; S Loche; C Pintor; F Camanni
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

8.  Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone.

Authors:  E Mazza; E Ghigo; S Goffi; M Procopio; E Imperiale; E Arvat; J Bellone; M F Boghen; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

9.  Acute administration of pyridostigmine and clonidine has an additive stimulatory effect on GH release in normal children.

Authors:  E Ghigo; S Goffi; E Mazza; E Imperiale; E Arvat; J Bellone; M Procopio; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1989-02       Impact factor: 4.256

10.  Effect of the enhancement of the cholinergic tone by pyridostigmine on the exercise-induced growth hormone release in man.

Authors:  M Cappa; A Grossi; S Benedetti; F Drago; S Loche; E Ghigo
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.